On May 5, 2025 Immorta Bio Inc, a scientific longevity company dedicated to "Treating Diseases of Aging and Treating Aging as Disease", reported a talk called "Immunologically Mediated Senolysis" at the "Clinical Immunology Symposium" of the American Association of Immunologists Annual Meeting (Press release, Immorta Bio, MAY 5, 2025, View Source [SID1234652528]). Immorta Bio’s talk will be accompanied by presentations from Pfizer1 and University of Pittsburgh2. The talk will occur Monday, May 5 | 8:15 AM – 10:15 AM | Room 316C at the Hawai’i Convention Center.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Immorta Bio is the first company to develop a "senolytic immunotherapy" for treatment of cancer and aging. This treatment comprises of training the immune system of patients to selectively kill "senescent cells" that promote aging and act as a shield to protect cancer against immune responses. By removing this defense mechanism, cancer becomes susceptible to immune attack.

The Company has shown that its lead senolytic immunotherapy product, SenoVax, is capable of destroying lung, breast, pancreatic and brain cancers, as well as melanoma3 in animal models.

"Having been chosen to present our work on using the immune system to fight cancer and aging in such an esteemed panel is truly an honor," said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio.

T cell mediated mechanisms of how SenoVax enables its anticancer effects have previously been published in the peer-reviewed literature with collaborators at University of California San Diego, Georgetown University, Ceders Sainai, and Calidi Bio4. Additionally, the Company recently demonstrated that natural killer cell activation as a result of SenoVax therapy also plays a role in stimulation of cancer destruction5.

"We have founded Immorta Bio on the principle of ‘Scientific’ Longevity," said Dr. Boris Reznik, President and CEO of Immorta Bio. "There is no better validation of our science than to be chosen to give an oral presentation at such a prestigious and exclusive scientific gathering as AAI2025."